Gene Therapy Research Brings New Hope for Inherited Blindness

Vision loss caused by inherited retinal diseases has long been considered irreversible. But new gene therapy research is beginning to challenge that assumption — offering real hope to families facing genetic blindness. A recently announced NIH‑funded study from West Virginia University highlights promising progress in gene therapy for inherited blindness, and it closely aligns with the long‑term mission of A Race Against Blindness (RAB) : accelerating awareness, research, and solutions for blinding genetic conditions. A Breakthrough in Gene Therapy for Inherited Blindness Researchers at West Virginia University were awarded a $1.4 million grant from the National Institutes of Health (NIH) to advance a novel gene therapy approach for PROM1‑related inherited retinal degeneration — a rare genetic condition that leads to progressive vision loss and blindness. The therapy uses a harmless viral vector to deliver functional genetic material directly into the retina. In preclinical mouse models, a single injection preserved or restored vision for more than a year , even when administered aft